Published in final edited form as:

Nat Rev Microbiol. 2019 March ; 17(3): 156–166. doi:10.1038/s41579-018-0129-6.

***Fusobacterium nucleatum* — symbiont, opportunist and oncobacterium**

Caitlin A. Brennan and Wendy S. Garrett*

Harvard T. H. Chan School of Public Health, Boston, MA, USA

Abstract

Fusobacterium nucleatum has long been found to cause opportunistic infections and has recently been implicated in colorectal cancer; however, it is a common member of the oral microbiota and can have a symbiotic relationship with its hosts. To address this dissonance, we explore the diversity and niches of fusobacteria and reconsider historic fusobacterial taxonomy in the context of current technology. We also undertake a critical reappraisal of fusobacteria with a focus on *F. nucleatum* as a mutualist, infectious agent and oncogenic microorganism. In this Review, we delve into recent insights and future directions for fusobacterial research, including the current genetic toolkit, our evolving understanding of its mechanistic role in promoting colorectal cancer and the challenges of developing diagnostics and therapeutics for *F. nucleatum*.

Omics technologies are providing new perspectives on what constitutes a pathogen, as well as the host and microbial features that contribute to pathogenesis, including for disease processes that are not classically regarded as infectious. Interest in microbiome science has led to the microbial sequence-based profiling of an unprecedented number of sample types and tissues and the identification of microbial signals in sites that previously were not considered to harbour microbial communities, although the reliability and relevance of these signals are not always clear. One bacterium that has garnered such attention recently in colorectal cancer microbiome studies is *Fusobacterium nucleatum*.

Fusobacteria are Gram-negative anaerobic bacilli with species-specific reservoirs in the human mouth, gastrointestinal tract and elsewhere. An association between the presence of *F. nucleatum* and human colorectal cancer has emerged across both patient populations and disease stages. *F. nucleatum* has long been considered as an opportunistic pathogen given its frequent isolation and identification in anaerobic samples from patients with different

* wgarrett@hsph.harvard.edu.

Author contributions

Both authors researched data for the article, made substantial contributions to discussions of the content, wrote the article and reviewed and edited the manuscript before submission.

Competing interests

W.S.G. serves on the Scientific Advisory Boards of Evelo Biosciences, Kintai Therapeutics and uBiome. W.S.G. is a consultant for BioMx and has been a consultant for Janssen, Pfizer and Merck. W.S.G. is a senior editor at eLife, which publishes the ‘Reproducibility Project: Cancer Biology’ experimental designs and methods as registered reports and results as replication studies.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41579-018-0129-6>.

infections. Although well known to the oral and medical microbiologist, the role of *F. nucleatum* as a cancer-causing member of the microbiota is still emerging and is revealing the multi-faceted ways in which a bacterium can contribute to the development, growth, spread of and treatment response to cancer. Herein, we undertake a critical reappraisal of fusobacteria with a focus on *F. nucleatum* as a mutualist, infectious agent and oncobacterium.

Fusobacterial diversity and niches

Despite the diversity of bacterial life, much of microbiological research has focused for a long time on certain lineages, such as Proteobacteria, on the basis of their importance to human health and agriculture, novelty in metabolic capability and, to an extent, ease of study (for example, because of culturability and genetic tractability). Increasingly, omics data are demonstrating that our current focus within the microbial world is limited given the diversity of unexamined microorganisms^{1,2} and the potential roles of less-studied micro-organisms in human disease and the environment. Fusobacteria, a distinct phylum of bacteria, are a prime example of previously understudied taxa. This phylum includes species commonly found in the human oral cavity (*Fusobacterium* spp.), human intestinal and urogenital tracts (*Leptotrichia* spp. and *Sneathia* spp., respectively), the intestinal tracts of fishes and whales (*Cetobacterium* spp.) and free-living in the marine environment (*Ilyobacter* spp.). Currently, the Fusobacteria are divided into two families: the Leptotrichiaceae, which include the *Leptotrichia*, *Sneathia*, *Sebaldella* and *Streptobacillus* genera, and the Fusobacteriaceae, including the marine and aquatic genera *Psychrilyobacter*, *Ilyobacter*, *Propionigenium* and *Cetobacterium* and the animal-associated *Fusobacterium* genus we highlight in this Review (Box 1). These understudied bacteria are Gram-negative, non-spore-forming, usually non-motile anaerobes that assume a tapered rod shape, and they can harbour unique metabolic capabilities, such as *Psychrilyobacter atlanticus*, which has been shown to break down nitramine explosives³.

Fusobacterium species are found in the mouth and other mucosal sites of humans and other animals, including mice (*Fusobacterium mortiferum*), macaques (*Fusobacterium simiae*), horses (*Fusobacterium equinum*) and even crocodile lizards (*Fusobacterium* spp.). Their presence in these healthy tissues suggests that they are natural constituents of the microbiota at these sites. However, as they have been frequently isolated from these same and other tissues in clinical samples during active disease, they are regarded as opportunistic pathogens. Of those species that colonize humans, *F. nucleatum* is the most abundant in the oral cavity and has come to the forefront of scientific interest in the past decade because of an increasing number of associations with extraoral diseases.

F. nucleatum as a mutualist

F. nucleatum has evolved in close association not just with the mammalian cells and tissues found in the oral cavity but also with the oral microbiota. *F. nucleatum* plays integral and beneficial roles in biofilms that contribute to both periodontal health and disease. In a dental plaque biofilm, *F. nucleatum* serves a structurally supportive role as a bridge organism, connecting primary colonizers such as *Streptococcus* species to the largely anaerobic

secondary colonizers to which it can also bind, including *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans*⁴ (fig. 1). With its elongated shape, *F. nucleatum* can interact with many other microbial cells. When co-cultured with *Streptococcus sanguinis*, *F. nucleatum* and *S. sanguinis* can assemble into highly ordered corn-cob-like structures, in which upwards of ten *S. sanguinis* cells can be bound to a single *F. nucleatum* cell⁵. Thus, the long rod shape of *F. nucleatum* is pivotal in facilitating structural relationships that are key for polymicrobial biofilms and interactions between microorganisms.

F. nucleatum also mediates important biofilm-organizing behaviour and interactions with host cells through the expression of numerous adhesins (fig. 1). The best characterized fusobacterial adhesin is RadD, which can bind the *Streptococcus mutans* adhesin SpaP to mediate the co-aggregation of these two bacteria and advanced biofilm organization^{6,7}. The role of RadD in fusobacterial adhesion is multifaceted — it mediates binding not only to bacteria but also to the yeast *Candida albicans*, which is also part of the oral microbiota⁸. Invasive *Fusobacterium* spp., including *F. nucleatum*, encode several membrane occupation and recognition nexus (MORN) repeat-containing proteins. Although an average of 30 copies of these domains can be found per *F. nucleatum* genome, their functional roles remain unclear^{9,10}. How this expanded class of proteins may influence the interactions of fusobacteria with other microorganisms and host cells is of great interest; however, their redundancy may also complicate dissection of their individual roles.

Microbial cells within biofilms engage not only in physical interactions but also in cross-feeding and metabolic interactions. Dissecting this chemical crosstalk in the complex communities of an in vivo biofilm is difficult, and simplified in vitro co-culture experiments are providing clarity on how microorganisms communicate with each other. Whereas such metabolic mutualism has been well described for other oral microorganisms, such as *P. gingivalis* and *Treponema denticola*¹¹, research on *F. nucleatum* and its partners is more limited. The most mechanistically developed example of cross-feeding is the ArcD-dependent excretion of ornithine by *Streptococcus gordonii*, which is then used by *F. nucleatum*, at least in culture¹². Broader metaproteomic analyses have also suggested that metabolic pathways in *F. nucleatum*, including amino acid fermentation and glycolysis, may be influenced by other microorganisms in a species-specific manner¹³. Parsing the metabolic languages used among the micro-organisms in the mutualistic oral biofilms remains an exciting area of inquiry. Recent work using the multiplex visualization method combinatorial labelling and spectral imaging–fluorescence in situ hybridization (CLASI-FISH) has suggested that the biogeography of plaque biofilms, and the role of *F. nucleatum* therein, may be more complex than previously thought, both in structure and in variations across plaque location¹⁴. Despite half a century of study on *F. nucleatum* and oral biofilms, current technologies are raising questions about whether we even know which microorganisms are in direct dialogue with *F. nucleatum* in its mutualistic niche.

***F. nucleatum* as an infectious agent**

Whereas *F. nucleatum* has a mutualistic relationship with the other members of the oral microbiota, its interactions with human tissues — whether oral or extraoral — span from

neutral to pathogenic in nature. Although the oral biofilms it helps coordinate are found on tooth surfaces in healthy individuals, *F. nucleatum* is also important in periodontitis as it directly shapes host responses and increases the infectivity of other pathogens. Specifically, *F. nucleatum* can induce expression of the antimicrobial peptide β -defensin 2 and pro-inflammatory cytokines, including IL-6 and IL-8, in the oral epithelium^{15–17}. Such *F. nucleatum*-driven inflammation contributes to disease progression in a model of oral tumorigenesis¹⁸. In these pathogenic settings, *F. nucleatum* influences the function of immune cells, such as myeloid cells, in which it activates NF- κ B, resulting in TNF production¹⁹. As periodontitis is a polymicrobial disease, unravelling how *F. nucleatum* interacts with other oral microorganisms to drive disease is of utmost importance. Co-infection of macrophages by both *F. nucleatum* and *P. gingivalis* blunts inflammasome activation compared with infection with *F. nucleatum* alone²⁰. Beyond modulating these host responses, *F. nucleatum* also increases the invasive potential of *P. gingivalis*^{21,22}, suggesting that these bacteria act cooperatively to evade destruction by the immune system and to develop an inflammatory-permissive environment during periodontitis.

The contribution of *F. nucleatum* to extraoral diseases remains rather mechanistically speculative. Although *F. nucleatum* has been isolated from clinical specimens in a variety of diseases, including appendicitis²³, brain abscesses²⁴, osteomyelitis²⁵, pericarditis²⁶ and adverse pregnancy outcomes such as chorioamnionitis²⁷ (fig. 2), the role of *F. nucleatum* in these pathologies remains unclear. Some have suggested that *F. nucleatum* is a passenger in these disease states rather than a disease driver²⁸. However, *F. nucleatum* can promote inflammatory responses, as discussed in periodontitis, and can bind and/or invade diverse cell types, including oral, colonic and placental epithelial cells^{29–31}, T cells³², keratinocytes³³ and macrophages³⁴, among others. Taken together, these observations suggest that *F. nucleatum* may have a causative role in several infections, but they do not provide evidence to confirm Koch's postulates.

Adverse pregnancy outcomes, such as placental infections and pre-term birth, are the extraoral diseases with the most data supporting a role for *F. nucleatum* as a driver or causative agent of disease. *F. nucleatum* is the most common organism isolated from amniotic fluid in pre-term births and can invade the relevant cell type — human umbilical endothelial cells³⁵. Furthermore, preclinical studies that used mouse models have demonstrated that *F. nucleatum* can localize to the placenta and induce stillbirths in mice when given intravenously³⁵. A specific *F. nucleatum* adhesin, FadA, has been implicated in these functions^{30,36,37}. Given these observations, *F. nucleatum* appears to be a bona fide placental pathogen; however, *Fusobacterium* spp. may also be part of the healthy placental microbiota³⁸. The detection of *Fusobacterium* spp. in healthy tissues raises the question of whether the frequency with which *F. nucleatum* is isolated from diseased placentae and amniotic fluid is due, in part, to sampling bias, as pathological tissues are more frequently examined than healthy placentae. Therefore, as in the oral cavity, *F. nucleatum* may prove to be pathogenic in the placenta only under certain conditions or by specific strains.

***F. nucleatum* and cancer**

Omics and epidemiological associations.

The concept of a microbial role in cancer is not novel — bacteria, parasites and viruses are all associated with potentiating cancer. Human papillomavirus drives mutational changes that lead to cervical cancer and the *cag* pathogenicity island of *Helicobacter pylori* shapes a tumour-permissive microenvironment in the gastric mucosa³⁹. Further, microbial ‘harbingers’ of cancer have historically been used to trigger diagnostic evaluations, such as the presence of *Streptococcus gallolyticus* bacteraemias for colorectal cancer. The omics explosion has expanded these insights by providing information about the microbial signatures of different cancerous and pre-cancerous tissues. In efforts to define the genomic and transcriptomic profiles of colorectal cancer tissues, investigators have found themselves with an unanticipated bounty of microbial information. Using different computational approaches, two studies in 2012 were the first to observe fusobacterial DNA⁴⁰ or RNA⁴¹ among the vastly more abundant human nucleic acids. Further, the fusobacterial signal was specifically enriched in the tumour tissues relative to adjacent normal tissues, and deeper analysis revealed these sequences to be *F. nucleatum*. These observations were surprising, although *F. nucleatum* has been isolated from gastrointestinal infections including appendicitis²³ and has also recently been associated with inflammatory bowel disease^{29,42,43}, suggesting a role in gastrointestinal pathologies.

That *F. nucleatum* nucleic acids are present in colorectal cancer tissues has since been confirmed in several different studies using varied molecular approaches (16S ribosomal RNA (rRNA) gene amplicon sequencing, DNA sequencing (DNA-seq), RNA sequencing (RNA-seq) and directed quantitative PCR (qPCR)) and with fluorescent in situ hybridization. Such imaging-based data of bowel tumours suggest that *F. nucleatum* is in intimate association with the colorectal crypts⁴⁴ and is perhaps even intracellular⁴⁰. Further, and very importantly, that viable *F. nucleatum* is present in these tissues has been verified by isolating *F. nucleatum* strains directly from biopsy samples^{41,45} and from patient-derived xenografts passaged in mice⁴⁶. Many independent studies have since observed this association in biopsy and faecal samples throughout different stages of colorectal cancer progression^{40,41,44,47}, different subsets of colorectal cancer (for example, serrated neoplasia)⁴⁸ and across patient populations, including American, European and Asian cohorts^{40,49}, although some studies have not reproduced these observations (see Box 2). That such associations can be made and confirmed across these different tissue types and cohorts implies a robustness in the association between *F. nucleatum* and colorectal tumorigenesis that merits its continued study. Recent studies examining other cancer types have also reported *F. nucleatum* in oral, head and neck, oesophageal, cervical and gastric cancer tissues^{50–54}. However, below, we focus on its role in colorectal cancer, as there is the most experimental support for a mechanistic role of *F. nucleatum* in driving tumorigenesis rather than acting as a microbial ‘passenger’ in this cancer type²⁸.

Continued probing of human tissues has revealed features of the association between *F. nucleatum* and colorectal cancer that suggest additional complexity. First, *F. nucleatum* is often found co-occurring in tumours with other oral microorganisms, including

Peptostreptococcus spp. and *Leptotrichia* spp., which mirrors how they are found interacting in the oral cavity^{46,55}. *F. nucleatum* is also frequently found in the same tumours as *Campylobacter* spp.⁵⁵, which are emerging as important gastrointestinal pathogens. Using microscopy on freshly resected tissues, researchers have shown that, in some patients, cancerous and nearby normal tissues harbour microorganisms that are arranged in highly organized, biofilm-like structures, which may influence how they contribute to tumorigenesis⁵⁶. Such observations support the merits of continued research into how the conversations between these microorganisms, whether in the oral cavity or colorectal tumours, may function as a contributing factor to pathogenesis and/or a target for therapeutic interventions. Another avenue for further examination is a potential co-exclusionary relationship between certain microorganisms, such as *Faecalibacterium prausnitzii*, and *F. nucleatum*, the latter of which harbours some bactericidal properties against these putative beneficial microorganisms⁵⁷.

Although experimental research into the mechanisms by which *F. nucleatum* influences colorectal cancer is ongoing, epidemiological studies have enabled timely advances into the connections between intratumoural *F. nucleatum* levels and colorectal tumorigenesis. The most striking of these observations is that high *F. nucleatum* abundance is associated with poorer patient prognosis⁵⁸ and cancer recurrence owing, in part, perhaps, to *F. nucleatum* promoting resistance to chemotherapy in colorectal cancer tissues⁵⁹. By linking *F. nucleatum* abundance to specific tumour phenotypes, such research has further supported the hypothesis that *F. nucleatum* influences the tumour microenvironment in consistent ways that may be ultimately exploited to shape colorectal cancer treatment. *F. nucleatum*-high colonic lesions (either malignant or pre-malignant) have further been subtyped according to microsatellite stability⁵⁸, CpG island methylator phenotype (CIMP) status^{60,61}, those bearing certain mutations (*BRAF*, *KRAS*, *TP53* and others) and localization to the proximal versus transverse or sigmoid colon^{61,62}. Collectively, these data support that there are links between *F. nucleatum* and tumour genetics and epigenetics that warrant further research. In the near future, tumoural microorganisms might be as influential as tumoural host genetics in guiding prognosis and treatment decisions, and microbial profiling may soon become as routine as tests of the genetic tumour profile. Tumours with a high *F. nucleatum* burden also have reduced T cell density⁶³, supporting experimental research that *F. nucleatum* contributes to antitumour immunity. Epidemiological studies have also begun to address how exposures and lifestyle, such as diet and antibiotics, may influence *F. nucleatum* abundance in the setting of colorectal cancer^{64,65}, prompting consideration of whether interventions designed to influence *F. nucleatum* levels in the body are beneficial for the prevention of colorectal cancer or detrimental to one's native microbiota.

Mechanisms to promote cancer.

How does *F. nucleatum*, which is adapted to a life in the oral cavity, mechanistically influence colorectal tumorigenesis? Directed sequencing studies have suggested that intratumoural *F. nucleatum* strains have an oral origin, as patients who harbour *F. nucleatum* in their tumours also have oral *F. nucleatum* strains that share matching arbitrarily primed PCR strain-typing patterns⁶⁶. However, such studies should be confirmed and merit further investigation with whole-genome sequencing to determine the true level of similarity

between oral and tumoural strains. If one assumes that tumoural *F. nucleatum* originates in the oral cavity, then *F. nucleatum* must first migrate to dysplastic tissues to exert its effect on tumorigenesis. Colorectal cancer tissues overexpress a specific sugar residue, Gal-GalNAc⁶⁷, which can be recognized by the fusobacterial adhesin Fap2, which also mediates co-aggregation and haemagglutination functions^{68,69}. A study using an orthotopic graft model showed that *F. nucleatum* localized to colorectal tumours in an Fap2-dependent manner via a haematogenous route, which mimics the transient bacteraemia that can occur after flossing or dental procedures^{70,71}. However, *F. nucleatum* has been found in colorectal cancer tissues at early stages of tumorigenesis⁴⁴ before Gal-GalNAc overexpression, suggesting that there may be multiple routes by which localization to the developing tumour microenvironment occurs. In experiments using the genetic *Apc*^{Min/+} model, in which mice spontaneously develop intestinal tumours^{72,73}, oral instillation of *F. nucleatum* was sufficient to potentiate colorectal tumour development, suggesting that an oral–gastrointestinal route is another possibility^{74,75}. *F. nucleatum* is considered to be an active invader of host cells. It encodes an array of genes related to adhesion and invasion⁹, enabling it to reside intracellularly in tumour cells, and, once there, potentially affecting the mechanisms by which it can influence tumorigenesis.

The spectrum of host processes that drive tumorigenesis, from mutations and genome instability to immune evasion, have been well described⁷⁶. What remains less clear is the breadth of these pathways that can be influenced by cancer-associated microorganisms such as *F. nucleatum*. Other colorectal-cancer-associated micro-organisms, such as enterotoxigenic *Bacteroides fragilis* and colibactin-producing *Escherichia coli*, produce toxins that either change the immune response or damage DNA, respectively^{75,77}. Although epidemiological associations suggest that *F. nucleatum* can promote genome instability and mutation⁶⁰, *F. nucleatum* encodes no known toxins and very few canonical ‘virulence factors’^{9,10,78}. Despite the resistance of *F. nucleatum* to genetic manipulation (see Box 3), researchers have made substantial progress into different mechanisms by which *F. nucleatum* may shape the tumour microenvironment (fig. 3).

Cancer is, at its simplest, uncontrolled cell growth, and *F. nucleatum* may influence the proliferation of colorectal cancer cells, either in pure cell culture^{59,79} or in ex vivo xenografts⁴⁶. Antibiotic treatment disrupted tumour growth in mice with *F. nucleatum*-bearing patient-derived colorectal cancer xenografts and reduced fusobacterial burden and cell proliferation⁴⁶. Work in cancer cell lines has provided a potential mechanism for such cancer-promoting effects, as FadA interacts with E-cadherin, leading to β -catenin activation and sub-sequent activation of Wnt target genes⁷⁹, an important pathway in cell development that is often dysregulated in cancer⁸⁰. Another axis of cancer development and progression that *F. nucleatum* influences is the creation of a pro-inflammatory tumour milieu. Using the same *Apc*^{Min/+} model in which mice fed *F. nucleatum* developed more colorectal and small intestinal tumours than their sham-fed counterparts, researchers also observed more intratumoural myeloid cells, including macrophages, dendritic cells and myeloid-derived suppressor cells, and this response was specific to *F. nucleatum*⁷⁴. In this model, *F. nucleatum* also activated the NF- κ B pathway and induced expression of the genes encoding several pro-inflammatory cytokines, including TNF, IL-6, IL-8 and IL-1 β , which mirrors human RNA-seq data from patients bearing high *F. nucleatum* loads in their colorectal

tumours⁷⁴. A third mechanism by which *F. nucleatum* shapes the tumour microenvironment is by evading anti-cancer immune responses. Fap2, the same adhesin that may mediate recognition and binding of the bacterium to colorectal cancer tissue, can bind a human receptor known as TIGIT that is expressed on natural killer (NK) cells and other tumour-infiltrating lymphocytes⁴⁵. TIGIT inhibits the cytotoxic function of these cells and thereby protects both *F. nucleatum* and nearby tumour cells from being killed by immune cells⁸¹. These three examples demonstrate just a snapshot of the diverse ways by which *F. nucleatum* can promote a pro-tumourigenic environment, and there are undoubtedly others that remain to be discovered.

Diagnostics and therapeutic approaches

Intrinsic to development of any fusobacterial diagnostic are two overarching questions: is *F. nucleatum* a biological marker for colorectal tumours and what is a robust, objective measure of *F. nucleatum* (see Box 4)? Faecal-based tests are used globally to screen for colorectal cancer. The most widely used test detects blood that is hidden in the stool (occult blood). Although this is a helpful screening test, the test is not specific as occult blood in the stool can be a harbinger of many diseases, not only colorectal cancer. Furthermore, in some faecal-based tests, many ingested substances can lead to a false-positive result. However, newer tests have increased the sensitivity and specificity for detecting occult blood, and some even detect DNA mutations in host cells shed into the stool. Adding microbial biomarkers (see Box 4), such as the faecal abundance of *F. nucleatum*, may provide much-needed progress in the ability to non-invasively screen for colorectal cancer. Beyond stool-based diagnostics, detection of IgA or IgG antibodies against *F. nucleatum* in the serum also has potential as a diagnostic⁸². However, population-based studies are required to further vet the specificity and sensitivity of a serum antibody-based test, and the genetic and antigenic diversity of *F. nucleatum* as well as a prior history of periodontitis or other fusobacterial infections may be confounding factors.

Effective tests designed to detect *F. nucleatum* in stool or tissue may have other uses beyond diagnosis. A high abundance of tumoural *F. nucleatum* may influence overall survival⁵⁸; thus, tumoural levels of *F. nucleatum* may some-day guide prognosis. Some studies suggest that there may be associations between the abundance of *F. nucleatum* and the genetic landscape of the tumour, which suggests that the effect of *F. nucleatum* on prognosis may not be a direct association. It remains understudied, but of interest, how the status of *KRAS* and *TP53* mutations, the presence of microsatellite instability and epigenetic dysregulation within a tumour (for example, CIMP)⁶⁰ affect and influence the tumoural load of *F. nucleatum*. A recent study suggested that patients with familial adenomatous polyposis with congenital *APC* mutations had undetectable levels of *F. nucleatum* in their tumours⁸³, which suggests that host genetics may have a role in shaping the burden of *F. nucleatum*. However, *F. nucleatum* did potentiate tumorigenesis in mouse models harbouring *Apc* mutations^{74,84}. *F. nucleatum* seems to influence tumoural infiltration of myeloid cells⁷⁴, T cell phenotypes⁶³ and the cytotoxic activity of NK cells⁴⁵. Such findings ultimately may influence the types of immunotherapies offered to patients with colorectal cancer in the future⁸⁵. Similarly, when investigators delved into why *F. nucleatum* was abundant in the colorectal cancer tissue of patients whose cancer recurred after chemotherapy, they found that *F. nucleatum* may

modulate resistance to chemotherapy by activating autophagy and impairing chemotherapy-induced cancer cell death⁵⁹. These provocative findings not only may explain the correlation between the abundance of *F. nucleatum* and prognosis but also raise the question of whether patients with a high abundance of *F. nucleatum* at diagnosis might benefit from a *F. nucleatum*-directed therapy before, or concomitant with, conventional chemotherapy. There is an urgent need for both discovery-oriented and translational research focused on how the composition and function of the gut and tumoural microbiota affect not only the efficacy of chemotherapy, radiation therapy and immunotherapy but also the adverse events associated with such treatments.

If *F. nucleatum* influences the outcome of colorectal cancer, the response to cancer treatment and the risk of pre-term labour, then expanding the anti-*F. nucleatum* therapeutic armamentarium is worth considering. In general, most clinical isolates of *F. nucleatum* are sensitive to a number of antibiotics, including metronidazole, clindamycin and a number of β -lactam antibiotics with the exception of penicillin, for which resistance has been reported⁸⁶. In patient-derived xenograft models of colorectal cancer that showed an enrichment of *F. nucleatum*, treatment with metronidazole reduced tumour volumes⁴⁶. However, metronidazole broadly targets anaerobic bacteria; therefore, implementing such an intervention would be problematic in numerous ways as anaerobic bacteria also improve responses to chemotherapy and immunotherapy. Thus, a narrow-spectrum antibiotic that is specific for *F. nucleatum* and ideally targets only the tumour tissue would be of interest, especially given the mutualistic role of *F. nucleatum* in the oropharynx. However, owing to concerns about antibiotic resistance for both broad-spectrum and narrow-spectrum antibiotics, antivirulence strategies may be more opportune. The *F. nucleatum* adhesin Fap2 may be an attractive target as its lectin activities seem to promote enrichment of *F. nucleatum* in tumoural tissues⁶⁹ and as it also compromises antitumour immunity⁴⁵.

Given the global health burden of both pre-term birth and colorectal cancer, an *F. nucleatum*-directed vaccine warrants consideration not only in high-risk populations but potentially in larger populations. *F. nucleatum* vaccination has already been tried to combat breath malodour. These halitosis vaccines have targeted FomA, an outer membrane protein expressed by *F. nucleatum*, which functions in bacterial co-aggregation and biofilm formation⁸⁷. Unfortunately, no outcome data have been published on whether individuals receiving the vaccines for halitosis had a lowered incidence of colorectal cancer. A recent study investigated whether immunization with alkyl hydroperoxide reductase sub-unit C (AhpC) from *F. nucleatum* could protect mice from infection with the bacterium⁸⁸. The vaccination lowered levels of *F. nucleatum* in intestinal tissues in intragastrically inoculated mice and elicited IgA and IgG responses. Given the sophisticated methods used by modern-day vaccinologists to elicit specific types of immune responses (humoral versus T cell responses) and that some *F. nucleatum* strains have an intracellular phase²⁹, T cell-inducing vaccines similar to those targeting tuberculosis and malaria might represent a preferable strategy for *F. nucleatum*. Another approach that is gaining in enthusiasm is phage-based therapeutics, not only because of multidrug resistance but also because of the exquisite selectivity of phages. However, the intracellular phase of some *F. nucleatum* strains could present barriers for effective phage therapy, and the number of distinct *F. nucleatum* strains found in colorectal cancer tissues might also pose a challenge. Nevertheless, the potential of

phage-based therapeutics is tantalizing, especially for multidrug-resistant bacteria. Another option to change the tumoural and other human microbiota that potentially harbour *F. nucleatum* is microbial ecosystem replacement therapy, which uses consortia of designer microorganisms or carefully curated cocktails of human-derived isolates⁸⁹. Such approaches are in clinical trial for infection with *Clostridium difficile* and could potentially be used to exclude *F. nucleatum*. In summary, a gamut of potential therapeutics could be used to target *F. nucleatum*, relying on traditional and more innovative approaches and targeting *F. nucleatum*, the microbiota and/or the host.

Conclusions

F. nucleatum is a multifaceted bacterium that engages in diverse interactions with other microorganisms and humans that range from beneficial to detrimental in nature. More and more, as we study diseases linked to members of the microbiota, it is tempting to jump rapidly to clinical applications. However, both robust experimental approaches, be it within human cohorts or preclinical models, and reproducible results across microbiota studies are pivotal to bridge the translational gap and ensure that data are neither lost in translation nor mistranslated clinically.

As has been observed for the cancer-associated bacterium *H. pylori* in the setting of the stomach, disruption of co-evolved symbioses can have unintended consequences, as the presence of *H. pylori* seems to have protective effects for other diseases such as allergy^{90,91}, and not all strains of *H. pylori* are oncogenic. Control, elimination and eradication efforts may be appropriate to defeat some infectious diseases such as malaria, but considering elimination of bacteria such as *F. nucleatum* to prevent associated conditions including colorectal cancer may be premature. Before we consider such *F. nucleatum*-targeted treatments, we must uncover more about the basic biology of *F. nucleatum*, in both its natural niche and in other, potentially disease-associated, locations, and about how it influences the host cells and other microorganisms with which it is in intimate association. We must address how to define causation by *F. nucleatum* in the numerous diseases with which it is associated. We must better appreciate who is at risk of *F. nucleatum*-associated diseases such as colorectal cancer. Whereas *F. nucleatum* is fairly ubiquitous in the oral cavity, its usually low levels in the gut are increased in patients with inflammatory bowel disease⁴³ and can be modulated by factors such as diet⁹². Understanding how *F. nucleatum* strains and levels in the mouth and gut affect the risk of colorectal cancer may inform suitable candidates for interventions focused on the modulation of *F. nucleatum*. Only by continuing to investigate *F. nucleatum* across the gamut of its mutualistic and pathogenic lifestyles will we discover the divergent pathways that may be leveraged for diagnostic, preventive and therapeutic purposes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work is supported by US National Institutes of Health (NIH) grant R01CA154426. C.A.B. is the Dennis and Marsha Dammerman fellow of the Damon Runyon Cancer Research Foundation (DRG-2205-14).

References

1. Hug LA et al. A new view of the tree of life. *Nat. Microbiol* 1, 16048 (2016). [PubMed: 27572647]
2. Parks DH et al. Recovery of nearly 8,000 metagenome-assembled genomes substantially expands the tree of life. *Nat. Microbiol* 2, 1533–1542 (2017). [PubMed: 28894102]
3. Zhao J-S, Manno D & Hawari J *Psychrobacter atlanticus* gen. nov., sp. nov., a marine member of the phylum Fusobacteria that produces H₂ and degrades nitramine explosives under low temperature conditions. *Int. J. Syst. Evol. Microbiol* 59, 491–497 (2009). [PubMed: 19244428]
4. Kolenbrander PE, Palmer RJ, Periasamy S & Jakubovics NS Oral multispecies biofilm development and the key role of cell-cell distance. *Nat. Rev. Microbiol* 8, 471–480 (2010). [PubMed: 20514044]
5. Lancy P, Dirienzo JM, Appelbaum B, Rosan B & Holt SC Cornucob formation between *Fusobacterium nucleatum* and *Streptococcus sanguis*. *Infect. Immun* 40, 303–309 (1983). [PubMed: 6131871]
6. Guo L, Shokeen B, He X, Shi W & Lux R *Streptococcus mutans* SpaP binds to RadD of *Fusobacterium nucleatum* ssp. polymorphum. *Mol. Oral Microbiol* 32, 355–364 (2017). [PubMed: 27976528]
7. Kaplan CW, Lux R, Haake SK & Shi W The *Fusobacterium nucleatum* outer membrane protein RadD is an arginine-inhibitable adhesin required for interspecies adherence and the structured architecture of multispecies biofilm. *Mol. Microbiol* 71, 35–47 (2009). [PubMed: 19007407]
8. Wu T et al. Cellular components mediating coadherence of *Candida albicans* and *Fusobacterium nucleatum*. *J. Dent. Res* 94, 1432–1438 (2015). [PubMed: 26152186]
9. Manson McGuire A et al. Evolution of invasion in a diverse set of *Fusobacterium* species. *MBio* 5, e01864 (2014). [PubMed: 25370491] This publication is a comparative genomic analysis of sequenced *Fusobacterium* species focused on potential mechanisms of molecular pathogenesis.
10. Zanzoni A, Spinelli L, Braham S & Brun C Perturbed human sub-networks by *Fusobacterium nucleatum* candidate virulence proteins. *Microbiome* 5, 89 (2017). [PubMed: 28793925]
11. Tan KH et al. *Porphyromonas gingivalis* and *Treponema denticola* exhibit metabolic symbioses. *PLOS Pathog* 10, e1003955 (2014). [PubMed: 24603978]
12. Sakanaka A, Kuboniwa M, Takeuchi H, Hashino E & Amano A Arginine-ornithine antiporter ArcD controls arginine metabolism and interspecies biofilm development of *Streptococcus gordonii*. *J. Biol. Chem* 290, 21185–21198 (2015). [PubMed: 26085091]
13. Hendrickson EL et al. Proteomics of *Fusobacterium nucleatum* within a model developing oral microbial community. *Microbiologyopen* 3, 729–751 (2014). [PubMed: 25155235]
14. Mark Welch JL, Rossetti BJ, Rieken CW, Dewhirst FE & Borisy GG Biogeography of a human oral microbiome at the micron scale. *Proc. Natl Acad. Sci. USA* 113, E791–E800 (2016). [PubMed: 26811460] This publication is a technical re-exploration of the spatial organization of the microbiota in the oral cavity, revealing new layers of complexity.
15. Krisanaprakornkit S et al. Inducible expression of human beta-defensin 2 by *Fusobacterium nucleatum* in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. *Infect. Immun* 68, 2907–2915 (2000). [PubMed: 10768988]
16. Ahn S-H et al. Transcriptome profiling analysis of senescent gingival fibroblasts in response to *Fusobacterium nucleatum* infection. *PLOS ONE* 12, e0188755 (2017). [PubMed: 29190775]
17. Bhattacharyya S et al. FAD-I, a *Fusobacterium nucleatum* cell wall-associated diacylated lipoprotein that mediates human beta defensin 2 induction through Toll-like receptor-1/2 (TLR-1/2) and TLR-2/6. *Infect. Immun* 84, 1446–1456 (2016). [PubMed: 26930710]
18. Gallimidi AB et al. Periodontal pathogens *Porphyromonas gingivalis* and *Fusobacterium nucleatum* promote tumor progression in an oral-specific chemical carcinogenesis model. *Oncotarget* 6, 22613–22623 (2015). [PubMed: 26158901]

19. Park S-R et al. Diverse Toll-like receptors mediate cytokine production by *Fusobacterium nucleatum* and *Aggregatibacter actinomycetemcomitans* in macrophages. *Infect. Immun* 82, 1914–1920 (2014). [PubMed: 24566622]
20. Taxman DJ et al. *Porphyromonas gingivalis* mediates inflammasome repression in polymicrobial cultures through a novel mechanism involving reduced endocytosis. *J. Biol. Chem* 287, 32791–32799 (2012). [PubMed: 22843689]
21. Saito A et al. *Porphyromonas gingivalis* entry into gingival epithelial cells modulated by *Fusobacterium nucleatum* is dependent on lipid rafts. *Microb. Pathog* 53, 234–242 (2012). [PubMed: 23034475]
22. Metzger Z et al. Synergistic pathogenicity of *Porphyromonas gingivalis* and *Fusobacterium nucleatum* in the mouse subcutaneous chamber model. *J. Endod* 35, 86–94 (2009). [PubMed: 19084132]
23. Swidsinski A et al. Acute appendicitis is characterised by local invasion with *Fusobacterium nucleatum/necrophorum*. *Gut* 60, 34–40 (2011). [PubMed: 19926616]
24. Han XY et al. Fusobacterial brain abscess: a review of five cases and an analysis of possible pathogenesis. *J. Neurosurg* 99, 693–700 (2003). [PubMed: 14567605]
25. Gregory SW, Boyce TG, Larson AN, Patel R & Jackson MA *Fusobacterium nucleatum* osteomyelitis in 3 previously healthy children: a case series and review of the literature. *J. Pediatr. Infect. Dis. Soc* 4, e155–e159 (2015).
26. Truant AL, Menge S, Milliorn K, Lairscey R & Kelly MT *Fusobacterium nucleatum* pericarditis. *J. Clin. Microbiol* 17, 349–351 (1983). [PubMed: 6833485]
27. Altshuler G & Hyde S Clinicopathologic considerations of fusobacteria chorioamnionitis. *Acta Obstet. Gynecol. Scand* 67, 513–517 (1988). [PubMed: 3071072]
28. Tjalsma H, Boleij A, Marchesi JR & Dutilh BE A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. *Nat. Rev. Microbiol* 10, 575–582 (2012). [PubMed: 22728587]
29. Strauss J et al. Invasive potential of gut mucosa-derived *Fusobacterium nucleatum* positively correlates with IBD status of the host. *Inflamm. Bowel Dis* 17, 1971–1978 (2011). [PubMed: 21830275]
30. Ikegami A, Chung P & Han YW Complementation of the *fadA* mutation in *Fusobacterium nucleatum* demonstrates that the surface-exposed adhesin promotes cellular invasion and placental colonization. *Infect. Immun* 77, 3075–3079 (2009). [PubMed: 19398541]
31. Han YW et al. Interactions between periodontal bacteria and human oral epithelial cells: *Fusobacterium nucleatum* adheres to and invades epithelial cells. *Infect. Immun* 68, 3140–3146 (2000). [PubMed: 10816455]
32. Kinder Haake S & Lindemann RA *Fusobacterium nucleatum* T18 aggregates human mononuclear cells and inhibits their PHA-stimulated proliferation. *J. Periodontol* 68, 39–44 (1997). [PubMed: 9029450]
33. Gursoy UK, Könönen E & Uitto V-J Intracellular replication of fusobacteria requires new actin filament formation of epithelial cells. *APMIS* 116, 1063–1070 (2008). [PubMed: 19133009]
34. Weiss EI et al. Attachment of *Fusobacterium nucleatum* PK1594 to mammalian cells and its coaggregation with periodontopathogenic bacteria are mediated by the same galactose-binding adhesin. *Oral Microbiol. Immunol* 15, 371–377 (2000). [PubMed: 11154434]
35. Han YW et al. *Fusobacterium nucleatum* induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth. *Infect. Immun* 72, 2272–2279 (2004). [PubMed: 15039352] This publication provides evidence in a preclinical model to support the association of fusobacteria with adverse pregnancy outcomes in humans.
36. Xu M et al. *FadA* from *Fusobacterium nucleatum* utilizes both secreted and nonsecreted forms for functional oligomerization for attachment and invasion of host cells. *J. Biol. Chem* 282, 25000–25009 (2007). [PubMed: 17588948]
37. Fardini Y et al. *Fusobacterium nucleatum* adhesin *FadA* binds vascular endothelial cadherin and alters endothelial integrity. *Mol. Microbiol* 82, 1468–1480 (2011). [PubMed: 22040113]
38. Aagaard K et al. The placenta harbors a unique microbiome. *Sci. Transl Med* 6, 237ra65 (2014).
39. Hatakeyama M *Helicobacter pylori* CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. *Cell Host Microbe* 15, 306–316 (2014). [PubMed: 24629337]

40. Kostic AD et al. Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma. *Genome Res* 22, 292–298 (2012). [PubMed: 22009990]
41. Castellarin M et al. *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Genome Res* 22, 299–306 (2012). [PubMed: 22009989]
42. Gevers D et al. The treatment-naïve microbiome in new-onset Crohn's disease. *Cell Host Microbe* 15, 382–392 (2014). [PubMed: 24629344]
43. Pascal V et al. A microbial signature for Crohn's disease. *Gut* 66, 813–822 (2017). [PubMed: 28179361]
44. McCoy AN et al. *Fusobacterium* is associated with colorectal adenomas. *PLOS ONE* 8, e53653 (2013). [PubMed: 23335968]
45. Gur C et al. Binding of the Fap2 protein of *Fusobacterium nucleatum* to human inhibitory receptor TIGIT protects tumors from immune cell attack. *Immunity* 42, 344–355 (2015). [PubMed: 25680274]
46. Bullman S et al. Analysis of *Fusobacterium* persistence and antibiotic response in colorectal cancer. *Science* 358, 1443–1448 (2017). [PubMed: 29170280]
47. Feng Q et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. *Nat. Commun* 6, 6528 (2015). [PubMed: 25758642]
48. Yu J et al. Invasive *Fusobacterium nucleatum* may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway. *Int. J. Cancer* 139, 1318–1326 (2016). [PubMed: 27130618]
49. Li Y-Y et al. Association of *Fusobacterium nucleatum* infection with colorectal cancer in Chinese patients. *World J. Gastroenterol* 22, 3227–3233 (2016). [PubMed: 27004000]
50. Al-Hebshi NN et al. Inflammatory bacteriome featuring *Fusobacterium nucleatum* and *Pseudomonas aeruginosa* identified in association with oral squamous cell carcinoma. *Sci. Rep* 7, 1834 (2017). [PubMed: 28500338]
51. Zhao H et al. Variations in oral microbiota associated with oral cancer. *Sci. Rep* 7, 11773 (2017). [PubMed: 28924229]
52. Audirac-Chalifour A et al. Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study. *PLOS ONE* 11, e0153274 (2016). [PubMed: 27115350]
53. Hsieh Y-Y et al. Increased abundance of *Clostridium* and *Fusobacterium* in gastric microbiota of patients with gastric cancer in Taiwan. *Sci. Rep* 8, 158 (2018). [PubMed: 29317709]
54. Yamamura K et al. Human microbiome *Fusobacterium nucleatum* in esophageal cancer tissue is associated with prognosis. *Clin. Cancer Res* 22, 5574–5581 (2016). [PubMed: 27769987]
55. Warren RL et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. *Microbiome* 1, 16 (2013). [PubMed: 24450771]
56. Dejea CM et al. Microbiota organization is a distinct feature of proximal colorectal cancers. *Proc. Natl Acad. Sci. USA* 111, 18321–18326 (2014). [PubMed: 25489084]
57. Guo S et al. A simple and novel fecal biomarker for colorectal cancer: ratio of *Fusobacterium nucleatum* to probiotics populations, based on their antagonistic effect. *Clin. Chem* 64, 1327–1337 (2018). [PubMed: 29914865]
58. Mima K et al. *Fusobacterium nucleatum* in colorectal carcinoma tissue and patient prognosis. *Gut* 65, 1973–1980 (2015). [PubMed: 26311717] This molecular epidemiology study highlights the association of tumoural fusobacterial levels with worse prognosis in colorectal cancer.
59. Yu T et al. *Fusobacterium nucleatum* promotes chemoresistance to colorectal cancer by modulating autophagy. *Cell* 170, 548–563 (2017). [PubMed: 28753429] This work explores the links between fusobacteria, colon cancer and autophagy, suggesting that fusobacteria may confer chemoresistance in colon cancers.
60. Tahara T et al. *Fusobacterium* in colonic flora and molecular features of colorectal carcinoma. *Cancer Res* 74, 1311–1318 (2014). [PubMed: 24385213]
61. Ito M et al. Association of *Fusobacterium nucleatum* with clinical and molecular features in colorectal serrated pathway. *Int. J. Cancer* 137, 1258–1268 (2015). [PubMed: 25703934]
62. Mima K et al. *Fusobacterium nucleatum* in colorectal carcinoma tissue according to tumor location. *Clin. Transl Gastroenterol* 7, e200 (2016). [PubMed: 27811909]

63. Mima K et al. *Fusobacterium nucleatum* and T cells in colorectal carcinoma. *JAMA Oncol* 1, 653–661 (2015). [PubMed: 26181352]
64. Mehta RS et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by *Fusobacterium nucleatum* in tumor tissue. *JAMA Oncol* 3, 921–927 (2017). [PubMed: 28125762]
65. Liu L et al. Diets that promote colon inflammation associate with risk of colorectal carcinomas that contain *Fusobacterium nucleatum*. *Clin. Gastroenterol. Hepatol* 16, 1622–1631 (2018). [PubMed: 29702299]
66. Komiya Y et al. Patients with colorectal cancer have identical strains of *Fusobacterium nucleatum* in their colorectal cancer and oral cavity. *Gut* 10.1136/gutjnl-2018-316661 (2018).
67. Yang GY & Shamsuddin AM Gal-GalNAc: a biomarker of colon carcinogenesis. *Histol. Histopathol* 11, 801–806 (1996). [PubMed: 8839767]
68. Copenhagen-Glazer S et al. Fap2 of *Fusobacterium nucleatum* is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. *Infect. Immun* 83, 1104–1113 (2015). [PubMed: 25561710]
69. Abed J et al. Fap2 mediates *Fusobacterium nucleatum* colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. *Cell Host Microbe* 20, 215–225 (2016). [PubMed: 27512904]
70. Carroll GC & Sebor RJ Dental flossing and its relationship to transient bacteremia. *J. Periodontol* 51, 691–692 (1980). [PubMed: 6937641]
71. Lockhart PB et al. Bacteremia associated with toothbrushing and dental extraction. *Circulation* 117, 3118–3125 (2008). [PubMed: 18541739]
72. Su LK et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. *Science* 256, 668–670 (1992). [PubMed: 1350108]
73. Moser AR, Pitot HC & Dove WF A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science* 247, 322–324 (1990). [PubMed: 2296722]
74. Kostic AD et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host Microbe* 14, 207–215 (2013). [PubMed: 23954159]
75. Wu S et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nat. Med* 15, 1016–1022 (2009). [PubMed: 19701202]
76. Hanahan D & Weinberg RA Hallmarks of cancer: the next generation. *Cell* 144, 646–674 (2011). [PubMed: 21376230]
77. Nougayrède J-P et al. *Escherichia coli* induces DNA double-strand breaks in eukaryotic cells. *Science* 313, 848–851 (2006). [PubMed: 16902142]
78. Sanders BE, Umana A, Lemkul JA & Slade DJ FusoPortal: an interactive repository of hybrid MinION-sequenced *fusobacterium* genomes improves gene identification and characterization. *mSphere* 3, 284 (2018).
79. Rubinstein MR et al. *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/ β -catenin signaling via its FadA adhesin. *Cell Host Microbe* 14, 195–206 (2013). [PubMed: 23954158] This publication and reference 74 are seminal papers supporting that *fusobacteria* potentiate colonic tumorigenesis.
80. White BD, Chien AJ & Dawson DW Dysregulation of Wnt/ β -catenin signaling in gastrointestinal cancers. *Gastroenterology* 142, 219–232 (2012). [PubMed: 22155636]
81. Dougall WC, Kurtulus S, Smyth MJ & Anderson AC TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. *Immunol. Rev* 276, 112–120 (2017). [PubMed: 28258695]
82. Wang H-F et al. Evaluation of antibody level against *Fusobacterium nucleatum* in the serological diagnosis of colorectal cancer. *Sci. Rep* 6, 33440 (2016). [PubMed: 27678333]
83. Dejea CM et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. *Science* 359, 592–597 (2018). [PubMed: 29420293]
84. Wu Y et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis in mice via a Toll-like receptor 4/p21-activated kinase 1 cascade. *Dig. Dis. Sci* 63, 1210–1218 (2018). [PubMed: 29508166]
85. Routy B et al. The gut microbiota influences anticancer immunosurveillance and general health. *Nat. Rev. Clin. Oncol* 15, 382–396 (2018). [PubMed: 29636538]

86. Bennett JE, Dolin R & Blaser MJ Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease (Elsevier Health Sciences, 2014).
87. Liu P-F, Huang I-F, Shu C-W & Huang C-M Halitosis vaccines targeting FomA, a biofilm-bridging protein of *Fusobacterium nucleatum*. *Curr. Mol. Med* 13, 1358–1367 (2013). [PubMed: 23865430]
88. Guo S-H et al. Immunization with alkyl hydroperoxide reductase subunit C reduces *Fusobacterium nucleatum* load in the intestinal tract. *Sci. Rep* 7, 10566 (2017). [PubMed: 28874771]
89. Petrof EO, Claud EC, Gloor GB & Allen-Vercoe E Microbial ecosystems therapeutics: a new paradigm in medicine? *Benef. Microbes* 4, 53–65 (2013). [PubMed: 23257018]
90. Blaser MJ *Helicobacter pylori* and esophageal disease: wake-up call? *Gastroenterology* 139, 1819–1822 (2010). [PubMed: 21029801]
91. Blaser MJ *Helicobacter pylori* eradication and its implications for the future. *Aliment. Pharmacol. Ther* 11 (Suppl. 1), 103–107 (1997). [PubMed: 9146796]
92. O'Keefe SJD et al. Fat, fibre and cancer risk in African Americans and rural Africans. *Nat. Commun* 6, 6342 (2015). [PubMed: 25919227]
93. Duncan SH, Hold GL, Harmsen HJM, Stewart CS & Flint HJ Growth requirements and fermentation products of *Fusobacterium prausnitzii*, and a proposal to reclassify it as *Faecalibacterium prausnitzii* gen. nov., comb. nov. *Int. J. Syst. Evol. Microbiol* 52, 2141–2146 (2002). [PubMed: 12508881]
94. Jalava J & Eerola E Phylogenetic analysis of *Fusobacterium alocis* and *Fusobacterium sulci* based on 16S rRNA gene sequences: proposal of *Filifactor alocis* (Cato, Moore and Moore) comb. nov. and *Eubacterium sulci* (Cato, Moore and Moore) comb. nov. *Int. J. Syst. Bacteriol* 49, 1375–1379 (1999). [PubMed: 10555315]
95. Todd SM, Settlege RE, Lahmers KK & Slade DJ *Fusobacterium* genomics using MinION and illumina sequencing enables genome completion and correction. *mSphere* 3, 284 (2018).
96. Gupta RS & Sethi M Phylogeny and molecular signatures for the phylum *Fusobacteria* and its distinct subclades. *Anaerobe* 28, 182–198 (2014). [PubMed: 24969840]
97. Nie S et al. *Fusobacterium nucleatum* subspecies identification by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J. Clin. Microbiol* 53, 1399–1402 (2015). [PubMed: 25653408]
98. Kook J-K et al. Genome-based reclassification of *Fusobacterium nucleatum* subspecies at the species level. *Curr. Microbiol* 74, 1137–1147 (2017). [PubMed: 28687946]
99. Repass J, Maherali N & Owen K Reproducibility project: cancer biology. Registered report: *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *eLife* 5, 427 (2016).
100. Repass J et al. Replication study: *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *eLife* 7, e64900 (2018).
101. Errington TM et al. An open investigation of the reproducibility of cancer biology research. *eLife* 3, 5773 (2014).
102. Boleij A et al. The *Bacteroides fragilis* toxin gene is prevalent in the colon mucosa of colorectal cancer patients. *Clin. Infect. Dis* 60, 208–215 (2015). [PubMed: 25305284]
103. Arthur JC et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science* 338, 120–123 (2012). [PubMed: 22903521]
104. Kinder-Haake S, Yoder S & Hunt Gerardo S Efficient gene transfer and targeted mutagenesis in *Fusobacterium nucleatum*. *Plasmid* 55, 27–38 (2006). [PubMed: 16115683] This foundational paper establishes techniques for genetic manipulation of *fusobacteria*.
105. Nakagaki H et al. *Fusobacterium nucleatum* envelope protein FomA is immunogenic and binds to the salivary statherin-derived peptide. *Infect. Immun* 78, 1185–1192 (2010). [PubMed: 20008529]
106. Han YW et al. Identification and characterization of a novel adhesin unique to oral *fusobacteria*. *J. Bacteriol* 187, 5330–5340 (2005). [PubMed: 16030227]
107. Casasanta MA et al. A chemical and biological toolbox for Type Vd secretion: characterization of the phospholipase A1 autotransporter FplA from *Fusobacterium nucleatum*. *J. Biol. Chem* 292, 20240–20254 (2017). [PubMed: 29021252]

108. Ma L, Ding Q, Feng X & Li F The protective effect of recombinant FomA-expressing *Lactobacillus acidophilus* against periodontal infection. *Inflammation* 36, 1160–1170 (2013). [PubMed: 23644821]
109. Wu C et al. Forward genetic dissection of biofilm development by *Fusobacterium nucleatum*: novel functions of cell division proteins FtsX and EnvC. *MBio* 9, 101 (2018). This recent publication expands the fusobacterial genetic toolkit.
110. Han YW, Ikegami A, Chung P, Zhang L & Deng CX Sonoporation is an efficient tool for intracellular fluorescent dextran delivery and one-step double-crossover mutant construction in *Fusobacterium nucleatum*. *Appl. Environ. Microbiol* 73, 3677–3683 (2007). [PubMed: 17449701]
111. Yang Y et al. *Fusobacterium nucleatum* increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor- κ B, and up-regulating expression of MicroRNA-21. *Gastroenterology* 152, 851–866 (2017). [PubMed: 27876571]
112. Kolenbrander PE, Andersen RN & Moore LV Coaggregation of *Fusobacterium nucleatum*, *Selenomonas flueggei*, *Selenomonas infelix*, *Selenomonas noxia*, and *Selenomonas sputigena* with strains from 11 genera of oral bacteria. *Infect. Immun* 57, 3194–3203 (1989). [PubMed: 2777378]
113. Tomkovich S et al. Locoregional effects of microbiota in a preclinical model of colon carcinogenesis. *Cancer Res* 77, 2620–2632 (2017). [PubMed: 28416491]
114. Kokes M et al. Integrating chemical mutagenesis and whole-genome sequencing as a platform for forward and reverse genetic analysis of *Chlamydia*. *Cell Host Microbe* 17, 716–725 (2015). [PubMed: 25920978]
115. Zarkavelis G et al. Current and future biomarkers in colorectal cancer. *Ann. Gastroenterol* 30, 613–621 (2017). [PubMed: 29118555]
116. Imperiale TF, Ransohoff DF & Itzkowitz SH Multitarget stool DNA testing for colorectal-cancer screening. *N. Engl. J. Med* 371, 187–188 (2014).
117. Nakatsu G et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. *Nat. Commun* 6, 8727 (2015). [PubMed: 26515465]
118. Peng B-J et al. Diagnostic performance of intestinal *Fusobacterium nucleatum* in colorectal cancer: a meta-analysis. *Chin. Med. J* 131, 1349–1356 (2018). [PubMed: 29786050]
119. Huang Q, Peng Y & Xie F Fecal fusobacterium nucleatum for detecting colorectal cancer: a systematic review and meta-analysis. *Int. J. Biol. Markers* 10.1177/1724600818781301 (2018).
120. Sze MA & Schloss PD Leveraging existing 16S rRNA gene surveys to identify reproducible biomarkers in individuals with colorectal tumors. *MBio* 9, 7 (2018).
121. Kaplan A et al. Characterization of aid1, a novel gene involved in *Fusobacterium nucleatum* interspecies interactions. *Microb. Ecol* 68, 379–387 (2014). [PubMed: 24643713]
122. Lima BP, Shi W & Lux R Identification and characterization of a novel *Fusobacterium nucleatum* adhesin involved in physical interaction and biofilm formation with *Streptococcus gordonii*. *Microbiologyopen* 6, e00444 (2017).
123. Park J, Shokeen B, Haake SK & Lux R Characterization of *Fusobacterium nucleatum* ATCC 23726 adhesins involved in strain-specific attachment to *Porphyromonas gingivalis*. *Int. J. Oral Sci* 8, 138–144 (2016).
124. Kinder SA & Holt SC Localization of the *Fusobacterium nucleatum* T18 adhesin activity mediating coaggregation with *Porphyromonas gingivalis* T22. *J. Bacteriol* 175, 840–850 (1993). [PubMed: 8380804]
125. Liu P-F et al. Vaccination targeting surface FomA of *Fusobacterium nucleatum* against bacterial co-aggregation: implication for treatment of periodontal infection and halitosis. *Vaccine* 28, 3496–3505 (2010). [PubMed: 20189489]
126. Bolstad AI, Jensen HB & Bakken V Taxonomy, biology, and periodontal aspects of *Fusobacterium nucleatum*. *Clin. Microbiol. Rev* 9, 55–71 (1996). [PubMed: 8665477]
127. Riordan T Human infection with *Fusobacterium necrophorum* (Necrobacillosis), with a focus on Lemierre's syndrome. *Clin. Microbiol. Rev* 20, 622–659 (2007). [PubMed: 17934077]

Box 1 | rethinking history and taxonomy of fusobacteria in the sequencing era

Beginning in the 1880s and 1890s, scientists noted fusiform rods in various zoonotic and human samples, including both healthy and diseased oral cavities. In the pre-sequencing era, *Fusobacterium* spp. were defined by their shape and their fermentation of amino acids and glucose to butyrate. On the basis of these criteria, one historic so-called *Fusobacterium* species frequently isolated from human faecal samples is now known as *Faecalibacterium prausnitzii*. By DNA analyses, *F. prausnitzii* is genetically more closely related to the Clostridiaceae⁹³. Since this realization, *Fusobacterium* spp. have not been considered to be quantitatively substantial members of the human faecal microbiota. Such misclassifications have also occurred for the oral bacteria now known as *Eubacterium sulci* and *Filifactor alocis*⁹⁴. Although not unique to fusobacteria, such misnomers highlight the heterogeneity of *Fusobacterium* spp. that lack conventional, characteristic phenotypes and can complicate delving into the historical literature record.

Genomic analyses have led to greater clarification not just between Fusobacteria and other phyla but also have improved the understanding of differences within *Fusobacterium* spp.^{9,78,95} (see the figure; adapted with permission from ref.⁹⁶, Elsevier). Phenotypically, the features that differentiate *Fusobacterium nucleatum* from other *Fusobacterium* spp. are largely metabolic and related to fermentation and secreted organic acid profiles, indole and hydrogen sulfide production and bile sensitivity, although these metrics have proved similarly ineffective in differentiating among *Fusobacterium* spp. as they have in distinguishing fusobacterial species from other phyla. Comparative genomics research suggests an adaptive radiation among these species resulting in three lineages^{9,96}. In this model, *F. nucleatum* evolved as a lineage with *Fusobacterium periodonticum*, and these species share not just a niche but also similar functions that are associated with invasion of host cells. *F. nucleatum* itself can be further delineated into four subspecies⁹⁷ — *nucleatum*, *animalis*, *vincentii* (inclusive of *fusiforme*) and *polymorphum* — although it has been argued that these subspecies are sufficiently divergent at a DNA level as to be considered separate species^{9,98}. Traditional consideration of these subspecies as largely either commensal (*polymorphum* and *vincentii*) or disease-associated (*nucleatum* and *animalis*) merits re-evaluation as fusobacterial isolates from colorectal tumours encompass all of these subspecies⁴⁵ (Supplementary table 1).

Box 2 | reproducibility in microbiome and cancer research

Detection of *Fusobacterium nucleatum* in colorectal cancer tissues across studies emerged as a challenge in the repass cancer replication study^{99,100} of the original 2012 study by Castellarin et al.⁴¹ and highlights the importance of reproducibility in science. this replication study, as part of the broader ‘reproducibility Project: Cancer Biology’, is an effort to replicate selected results from landmark publications in cancer biology¹⁰¹. a brief recap and contextualization of these two studies are as follows. in 2012, an rNa sequencing (rNa-seq)-based study found that *F. nucleatum* was enriched in colorectal cancer versus adjacent normal tissue, and DNa-based detection of *F. nucleatum* validated the rNa-seq-based findings⁴¹. similarly, an independent study also published in 2012 using different methodology also observed an enrichment of *F. nucleatum* DNa in colorectal cancer tissues compared with adjacent tissue using whole-genome shotgun sequencing and 16s ribosomal rNa (rrNa) gene amplicon survey data⁴⁰.

The Repass replication study (proposed in 2016 and published in 2018) used flash-frozen samples from patients with colorectal cancer and from healthy controls, which were not included in the original Castellarin et al. study, but the replication study used the same primer and probe set. similar and disparate taqMan primer and probe sets have been used in a number of studies since the Castellarin et al. publication. Namely, some reports used primers that are specific to *F. nucleatum* whereas others used more general primers that detect many *Fusobacterium* spp. this distinction is not trivial, as one study demonstrated that the immunological associations they observed were specific to *F. nucleatum* and not generalizable to *Fusobacterium* spp. levels⁶³. this situation is analogous to the difficulty of interpreting the presence and contribution of enterotoxigenic *Bacteroides fragilis* and colibactin-producing *Escherichia coli*, which are also colorectal-cancer-associated bacteria, in 16s rrNa surveys, which cannot differentiate these strains from other, commensal *B. fragilis* and *E. coli* species that are normally found in the gut^{102,103}. the stratification of tumours by *F. nucleatum* nucleic acid abundance has further limitations in that the distinction between *F. nucleatum*-high and *F. nucleatum*-low samples is subjective, especially as quantitative PCr (qPCr) values used to determine *F. nucleatum* levels approach the limit of detection¹⁰⁰. Notably, a range in *Fusobacterium*-positive colorectal cancers, 3–56%, deemed positive for fusobacteria has been observed across studies, all of which have used formalin-fixed paraffin-embedded (FFPe) tissue^{58,61–64}. the repass study did not observe the degree of enrichment of *F. nucleatum* in tumour versus adjacent normal colorectal tissue published in Castellarin et al. Given the differences observed across studies that have used different PCr-based methods and distinct sample types (FFPe versus flash-frozen), the extent to which *Fusobacterium* spp. are enriched in colorectal tumours varies across patient populations. stage, tumour location along the bowel and underlying genetics may be an underlying cause of these disparate observations. One critical question that emerged from these studies is whether fusobacterial nucleic acids are an appropriate metric at all. One recent study suggests that a ratio of *F. nucleatum* to other bacterial strains (for example, *Faecalibacterium prausnitzii* or *Bifidobacterium* spp.) measured by qPCr stool-based assay performs better as a potential diagnostic biomarker than *F. nucleatum* alone⁵⁷.

Box 3 | Tools and methodological approaches for studying fusobacterial biology

The study of fusobacterial biology has been restricted to this point by the limited genetic tractability of these strains. in the published literature, only four strains have been mutagenized: *Fusobacterium nucleatum* subsp. *nucleatum* strains atCC 23726 (ref.¹⁰⁴) and atCC 25586 (ref.¹⁰⁵); *F. nucleatum* subsp. *polymorphum* atCC 10953 (ref.¹⁷) by electroporation; and *F. nucleatum* subsp. *polymorphum* 12230 by sonoporation¹⁰⁶. this technical hurdle is multifactorial. Hypothesized biological limitations have included strain-intrinsic restriction endonuclease activity in response to different methylation patterns of heterologous DNA as well as that most constructs currently used are derived from constructs that were designed originally for *Clostridium* spp. given their comparably low GC content and similar codon biases. therefore, instead of genetic manipulation of *F. nucleatum*, researchers have used alternative approaches to mechanistically study specific adhesins and enzymes, such as heterologous expression of fusobacterial proteins in other species, including *Lactobacillus* spp. and *Escherichia coli*^{17,106–108}.

The clostridial research field has a more developed genetic toolkit, perhaps because of the comparably larger scientific community, whereas many of the tools still in use today in fusobacterial research were generated by Susan Kinder Haake, a pioneer in fusobacterial genetics and a master tool-builder in this field. after her death, the continued development of such resources with an eye towards broader community implementation stagnated until recently. two studies have now demonstrated transposon mutagenesis in *F. nucleatum* atCC 23726 (ref^{68,109}), the most genetically tractable strain described to date. Even more impressively, Wu et al.¹⁰⁹ have developed techniques to rapidly generate in-frame, nonpolar deletions, whereas most of the previously reported *F. nucleatum*-directed mutants were insertional (Campbell) mutants, which are often polar and prone to reversion without antibiotic selection. antibiotic-marked deletion and complementation fusobacterial strains have previously been generated using a unique sonoporation-based method, but to date, this approach has been successfully reported only in *F. nucleatum* by one laboratory^{30,110}. An important caveat to these studies is that *F. nucleatum* atCC 23726 is neither an oral nor gastrointestinal isolate but has a urogenital origin; therefore, its applicability to the study of different host–microorganism interactions may be limited. Furthermore, strain usage within and across studies has been inconsistent throughout *F. nucleatum* studies, and especially in the quickly expanding *F. nucleatum* colorectal cancer field (supplementary table 1). when an observation, such as increased host cell proliferation, is confirmed with distinct *F. nucleatum* isolates across laboratories, these studies underscore the robustness of an observed biological effect^{59,79,111}. However, the diversity of strains used across these works can also complicate generating a comprehensive model of how *F. nucleatum* potentiates colorectal cancer. For example, a mechanism by which *F. nucleatum* shapes the tumour microenvironment may be strain-specific, as has been previously observed for phenotypes in the oral setting, such as fusobacterial co-aggregation with other bacteria¹¹². this issue has already surfaced in the tumour-specific literature with conflicting observations in animal models of tumorigenesis using different *F. nucleatum* isolates^{45,69,74,79,113}.

In parallel to the ongoing development of more effective traditional tools (for example, forward genetics approaches) for fusobacterial genetics, the implementation of methods used in other microorganisms to advance the study of *F. nucleatum* in host–microorganism interactions is desperately needed. CrisPr–Cas9 technologies may enable expedient deletions and defined library generation of *F. nucleatum* mutants that could serve as a community resource. Chemical mutagenesis in conjunction with deep sequencing, using methods described for genetically recalcitrant or intracellular bacteria such as *Chlamydia trachomatis*¹¹⁴, could provide a much-needed breakthrough in understanding the niche specialization of *F. nucleatum*.

Box 4 | Faecal *Fusobacterium nucleatum*: how does one assess a biomarker?

Ideal biological markers (biomarkers) can result in efficient diagnosis with high sensitivity and specificity, can inform disease prognosis, and may provide valuable input guiding therapeutic decisions. there has been tremendous and longstanding interest in non-invasive biomarkers that use stool or serum for diagnosis of colorectal cancer^{115,116}. Given the links between *Fusobacterium nucleatum* and colorectal cancer, there has also been interest in the presence of *F. nucleatum* DNA and cells in stool and intestinal tissues and of antibodies against *F. nucleatum* as biomarkers of colorectal tumours and as prognostic factors in established colorectal cancer.

There have been a handful of studies characterizing the microbiome of colorectal adenomas and cancer^{40,41,44,117}. to increase the power of these admittedly small population studies (from dozens to hundreds of samples), a few individual research groups have undertaken meta-analyses to improve estimates of *F. nucleatum* presence in the stool and tissue, when colorectal cancer has been diagnosed. A meta-analysis from 2018 examined ten studies (seven peer-reviewed articles) that together included 629 patients with colorectal cancer and 569 healthy controls. in this meta-analysis, most studied subjects were from China, most of the samples were faecal and the measurement assays were mostly based on quantitative PCR (qPCR). the area under the curve (auC) of the receiver operator characteristic (rOC) curve was 0.86 (95% Ci 0.83–0.89), suggesting that *F. nucleatum* may be a good biomarker for colorectal cancer in some populations¹¹⁸. in general, an auC <0.5 suggests that a biomarker has no diagnostic value and an auC >0.90 suggests an excellent diagnostic value, with an auC of 0.75–0.9 falling in the range of good and 0.50–0.75 representing poor value. rOC curves are generated by graphing the true-positive rate (sensitivity) on the y-axis and 1 – the true-negative rate (specificity) on the x-axis at a variety of ‘cut-off’ values that distinguish healthy versus sick or, in this case, the absence versus presence of cancer. another 2018 meta-analysis (seven studies, six peer-reviewed publications) that exclusively focused on faecal *F. nucleatum* studies had a lower auC (0.8) and less encouraging specificity and sensitivity metrics overall. However, a subgroup analysis of studies with 50 asian subjects demonstrated improved specificity (0.85, 95% Ci 0.80–0.88)¹¹⁹. in complete contrast was another meta-analysis of 14 studies including over 1,700 faecal samples (16s ribosomal rNa (rrNa) gene amplicon surveys) and 492 intestinal tissue samples from 350 individuals in which neither *Fusobacterium* spp. nor *F. nucleatum* emerged as biomarkers for colorectal adenocarcinoma¹²⁰. Furthermore, in this meta-analysis, all individual fusobacterial taxa performed poorly in differentiating subjects that were healthy from those that had colorectal cancer, with auCs around 0.5–0.75. there was limited study overlap across these three meta-analyses regarding the method of microbial detection (qPCR versus 16s rrNa gene amplicon surveys). For a disease as prevalent as colorectal cancer, a much larger population-scale study (on the order of hundreds of thousands) would need to be undertaken to evaluate *F. nucleatum* as a diagnostic biomarker. Given that there might be differences due to subject ethnicity or geography, a global cohort would be ideal. Furthermore, the method of detection would not be a trivial decision.

Combinatorial labelling and spectral imaging– fluorescence in situ hybridization

(CLASI-FISH). This technique enables detection of ten to several hundred distinct microbial taxa by using combinations of fluorophores coupled to different oligonucleotide probes that target unique regions of the 16S ribosomal RNA (rRNA) gene.

Osteomyelitis

Infectious or non-infectious inflammation of the bone.

Pericarditis

Infectious or non-infectious inflammation of the sac-like tissue that surrounds the heart.

Chorioamnionitis

Infectious or non-infectious inflammation of the chorion and amnion (the fetal membranes) and the amniotic fluid, which can occur before or during labour.

Lemierre syndrome

Infectious thrombophlebitis of the internal jugular vein, which is often caused by *F. necrophorum*. It can occur in the setting of a fusobacterial throat infection with peritonsillar abscess formation, but in the modern antibiotic era it remains fairly rare. The syndrome is named after Andrew Lemierre, who published a case report in the 1930s that identified throat infections as the cause of several anaerobic sepsis cases.

CpG island methylator phenotype

(CIMP). A state of epigenetic instability in which promoter CpG island sites become hypermethylated, which results in turning off of genes, including tumour suppressor genes.

Microsatellite instability

A condition in which impaired DNA mismatch repair leads to genetic hypermutation. Colorectal tumours can be described as microsatellite instable-high (MSI-high) or microsatellite stable (MSS).

Familial adenomatous polyposis

A genetic disorder that is caused by mutation of the *APC* gene and results in numerous tumours of the large bowel. Classically, these colon tumours form during the teenage years and the number of tumours increases with age, but there are also attenuated variants.

Colorectal adenomas

Non-malignant tumours occurring in the colon and rectum that can develop into cancer.

Fig. 1. The organizing role of *Fusobacterium nucleatum* in oral biofilms.

In oral biofilms (left panel, as visualized by combinatorial labelling and spectral imaging–fluorescence in situ hybridization (CLASI-FISH); right panel, schematic to demonstrate specific interactions), *Fusobacterium nucleatum* functions as a bridging organism that adheres first to early colonizers of the dental surface such as *Streptococcus* spp. One mechanism for this interaction is the binding of the RadD adhesin of *F. nucleatum* to the streptococcal adhesin SpaP⁶. Two other fusobacterial adhesins, Aid1 and CmpA, have also been implicated in this interaction^{121,122}. Once adhered to the developing biofilm, *F. nucleatum* aggregates with the secondary colonizers such as *P. gingivalis* using the fusobacterial adhesins RadD, Fap2 and FomA^{68,123–125}. RadD mediates additional interactions between *F. nucleatum* and *Actinomyces naeslundii*⁷ and between *F. nucleatum* and the fungus *Candida albicans*⁸. Left panel reproduced with permission from ref.¹⁴, PNAS.

Fig. 2. oral and extraoral diseases associated with *Fusobacterium nucleatum*.

Fusobacterium nucleatum is one of the most commonly isolated oral bacteria in clinical infections, whether found alone or in polymicrobial infections (indicated by an asterisk)¹²⁶.

Unlike the related *Fusobacterium necrophorum*, for which a causative role in Lemierre syndrome is well established¹²⁷, whether *F. nucleatum* functionally contributes to each of these various diseases remains to be determined. We have scored the evidence linking *F. nucleatum* to the listed infections using a subjective assessment of both the breadth and depth of the existing literature with regard to isolation, association and experimental data in preclinical models. Beyond the oral cavity, there is the most mechanistic support for a role of *F. nucleatum* in adverse pregnancy outcomes and colorectal cancer. Further, the route of infection, oral or haematogenous, by which *F. nucleatum* may disseminate to these disparate sites remains to be clarified.

Fig. 3. Mechanisms by which *Fusobacterium nucleatum* may contribute to colorectal carcinogenesis.

Accumulating evidence suggests that *Fusobacterium nucleatum* influences many stages of colorectal cancer progression. First, *F. nucleatum* can increase cell proliferation in cancer cells through two distinct mechanisms: the binding of FadA to E-cadherin drives activation of the β -catenin and Wnt pathway⁷⁹, and activation of TLR4 and NF- κ B results in increased expression of the oncogenic microRNA miR21 (ref.¹¹¹). These observations are supported by work in the *Apc*^{Min/+} mouse model of intestinal tumorigenesis, in which *F. nucleatum* administration resulted in more aberrant crypt foci and high-grade dysplasia, both early stages of tumorigenesis⁷⁴. Once the tumour has developed, *F. nucleatum* can localize to the Gal-GalNAc-expressing tumour cells through binding of its Fap2 lectin, which results in enrichment of *F. nucleatum*⁶⁹. *F. nucleatum* functionally modifies the tumour microenvironment by influencing the accumulation of myeloid cells⁷⁴ and blocking antitumoural immune responses of natural killer (NK) cells⁴⁵. *F. nucleatum* may also affect metastatic dissemination as it can be isolated from liver and lymph node metastases^{40,41,46}. Once colorectal cancer is identified and treated, *F. nucleatum* is associated with increased risk of recurrence and the development of chemoresistance by suppressing specific miRNAs involved in autophagy⁵⁹. LPS, lipopolysaccharide.